Publications
5900 Results
- Journal / Conference
- Ther Adv Med Oncol. 2026 Jul 23;18:17588359261451739. doi: 10.1177/17588359261451739
- Year
- 2026
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- 42499790
- PMC
- PMC13396573
- Study Number(s)
- S1609
A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort
- Journal / Conference
- Annals of Oncology
- Year
- 2026
- Research Committee(s)
- Breast
- PMID
- 13488494
- PMC
- PMC42613139
- Study Number(s)
- S1007
Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER)
- Journal / Conference
- Int J Radiat Oncol Biol Phys. 2026 Jul 28:S0360-3016(26)04066-6.
- Year
- 2026
- Research Committee(s)
- Breast
- PMID
- 42520859
- Study Number(s)
- S1706
Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer
- Journal / Conference
- J Natl Cancer Inst . 2026 Jul 15:djag221. doi: 10.1093/jnci/djag221
- Year
- 2026
- Research Committee(s)
- Breast
- PMID
- 42458791
- Study Number(s)
- S1007
Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007)
- Journal / Conference
- NPJ Precision Oncology 2026 Jul 3;10(1):258. doi: 10.1038/s41698-026-01588-7.
- Year
- 2026
- Research Committee(s)
- Genitourinary
- PMID
- 42399473
- PMC
- PMC13332042
- Study Number(s)
- S1314
Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner
- Journal / Conference
- JAMA Oncology. Published online August 20, 2026. doi:10.1001/jamaoncol.2026.3026
- Year
- 2026
- Research Committee(s)
- Cancer Care Delivery
- PMID
- 42623089
- PMC
- PMC13494795
Federal and Industry Sponsorship in US Cancer Clinical Trials
- Journal / Conference
- JAMA Netw Open. 2026;9(7):e2625814. doi:10.1001/jamanetworkopen.2026.25814
- Year
- 2026
- Research Committee(s)
- Cancer Care Delivery
- PMID
- 42518232
- PMC
- PMC13416910
Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review
- Journal / Conference
- J Clin Oncol. Published online July 29, 2026. doi:10.1200/JCO-25-03052
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41864782
- PMC
- PMC13105325
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
- Journal / Conference
- Blood Adv. 2026 Jul 29:bloodadvances.2026021402. doi: 10.1182/bloodadvances.2026021402.
- Year
- 2026
- Research Committee(s)
- Lymphoma
- PMID
- 42526889
- Study Number(s)
- S1826
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)
- Journal / Conference
- Am J Hematol. 2026 Sep;101(9):2137-2146. doi: 10.1002/ajh.70398.
- Year
- 2026
- Research Committee(s)
- Lymphoma
- PMID
- 42240061
- PMC
- PMC13428379
- Study Number(s)
- S1001